Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Cancer Metastatic × margetuximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Recurrence 1 Breast Cancer Metastatic 1

Interventions

Fulvestrant 5 Letrozole 3 ribociclib 2 exemestane 2 dalpiciclib 2 apatinib 2 Gemcitabine 2 Capecitabine 2 Anastrozole 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 palbociclib 1 margetuximab 1 irinotecan sucrosofate 1 fluzoparib 1 abemaciclib 1 Vinorelbine 1 Trastuzumab 1 Tamoxifen 1 Paclitaxel 1 Liposomes 1 Irinotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Zai Lab (Hong Kong), Ltd.

Phase 2 Unknown

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡